What it's actually good for
Urolithin A is a metabolite your gut bacteria make from ellagitannins in pomegranate, walnuts, and berries — but production is wildly inconsistent between people, and a meaningful share of the population converts little to none of it from food regardless of how much they eat. Direct supplementation (as Mitopure) sidesteps that gut-bacteria lottery entirely by delivering a standardized dose instead of hoping your microbiome cooperates.
Mechanistically, urolithin A is the best-characterized human trigger of mitophagy — the selective clearance of damaged mitochondria, typically followed by growth of new ones. That's a genuinely interesting target for aging tissue, where an accumulation of dysfunctional mitochondria is thought to contribute to declining muscle and immune performance. The mechanism is well established in animal work; the open question is how much of it shows up as a measurable benefit in humans, and that's where the caveats start.
What the research says
The funding problem, up front. Every published human RCT on oral urolithin A — muscle, immune, or otherwise — has been funded by Amazentis SA, the company behind Mitopure and its retail brand, Timeline. Several of the studies are co-authored by Amazentis employees, equity holders, or the company's own founder and CEO. That doesn't make the data wrong, but it does mean there's no independently funded human RCT confirming any of these findings yet, and industry-funded supplement trials have a well-documented pattern of skewing more favorable than independently funded ones.
Muscle strength and endurance (Grade B). This is the strongest evidence urolithin A has. An 88-person, 4-month RCT in middle-aged adults found roughly 10-12% gains in leg strength versus a placebo group that declined, plus a meaningfully longer 6-minute-walk distance. A second RCT — 66 adults aged 65-90, also 4 months — missed its primary endpoint but found significantly improved muscle endurance (contractions to fatigue) by the two-month mark. A 2024 systematic review, independently funded though built on the same small pool of industry trials, pooled 5 studies and about 250 people and confirmed the direction of effect. Consistent signal, small evidence base, one funder.
Aerobic performance (Grade C). The same middle-aged-adult trial reported a ~10% within-group rise in VO2 peak at 1,000 mg/day, but the comparison against placebo only reached a statistical trend (p=0.058) — not significance. Unproven, not disproven.
Immune aging (Grade C). A 2025 Nature Aging trial — 50 adults, just 28 days, again Amazentis-funded — found urolithin A expanded a "younger," less-exhausted subset of CD8+ T cells and shifted immune-cell metabolism. It's a well-conducted trial, but it's one short study measuring biomarkers, not clinical outcomes like infection rates. Early and specific, not yet broad.
Skin and anti-aging (Grade C — thin). This is the weakest part of the pitch. No published human trial has tested whether swallowing urolithin A does anything for skin. The skin data that exists comes from topical urolithin A cream in small, unpublished, company-sponsored trials — a different product and route than the oral capsule reviewed here. If skin is your main reason for buying this, the evidence doesn't support it yet.
We used to file this page under the skin and anti-aging goal. We don't anymore. Indexing a product to a goal is a recommendation, and we shouldn't make one where our own grade says the evidence isn't there. The claim stays on the page because people search for it and deserve the answer. The goal tag is gone because the answer is no.
What Rhonda Patrick says. Her April 2026 FoundMyFitness episode on urolithin A lands in the same place this page does. She credits the biomarker and muscle-outcome shifts at 500-1,000 mg/day, then lists the primary endpoints that came back null: peak power, six-minute walk, maximal ATP production. She notes that most of the pivotal trials were short and involved the manufacturer, and that mouse lifespan results don't establish human longevity. Her summary is that compounds like this "may be useful for selected goals, but they are not universal anti-aging essentials."
How much, and which form
500 mg/day, as two 250 mg softgels, is the dose used in the positive muscle trials; some trials used 1,000 mg/day with similar results. Effects build slowly — the endurance gains in the older-adult trial didn't show up until month two, so this isn't a supplement you judge after a week.
Safety & interactions
Well-tolerated across every published trial, including 1,000 mg/day for up to 4 months, with no serious adverse events reported. It carries FDA GRAS status. That said, human safety data tops out at 4 months of continuous use — there's no multi-year data, and it hasn't been studied in pregnancy, nursing, or minors. No significant drug interactions have surfaced in trials, though formal interaction studies haven't been run. This is informational, not medical advice — check with a clinician before starting.
How we picked the brand
A urolithin A product earns a spot when it matches the 500 mg/day dose used in the published trials, discloses third-party testing, and — because this ingredient category is still dominated by one manufacturer's patented process — is transparent about being that same manufacturer's studied formulation rather than an unverified generic copy.